Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants

References

1. 1.↵
   1. Nardone B,
   2. Saddleton E,
   3. Laumann AE, et al

   . Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol 2014;44:173–80 doi:10.1007/s00247-013-2795-x pmid:24057195

   CrossRefPubMed
2. 2.↵
   American College of Radiology. ACR Manual on Contrast Media. Version 10.3. Reston: American College of Radiology; 2017
3. 3.↵
   1. Bedoya MA,
   2. White AM,
   3. Edgar JC, et al

   . Effect of intravenous administration of contrast media on serum creatinine levels in neonates. Radiology 2017;284:530–40 doi:10.1148/radiol.2017160895 pmid:28387639

   CrossRefPubMed
4. 4.↵
   1. Roberts DR,
   2. Chatterjee AR,
   3. Yazdani M, et al

   . Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016;37:2340–47 doi:10.3174/ajnr.A4891 pmid:27469211

   Abstract/FREE Full Text
5. 5.↵
   1. Hu HH,
   2. Pokorney A,
   3. Towbin RB, et al

   . Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016;46:1590–98 doi:10.1007/s00247-016-3646-3 pmid:27282825

   CrossRefPubMed
6. 6.↵
   1. Flood TF,
   2. Stence NV,
   3. Maloney JA, et al

   . Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017;282:222–28 doi:10.1148/radiol.2016160356 pmid:27467467

   CrossRefPubMed
7. 7.↵
   1. Radbruch A,
   2. Haase R,
   3. Kickingereder P, et al

   . Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. Radiology 2017;283:828–36 doi:10.1148/radiol.2017162980 pmid:28273007

   CrossRefPubMed
8. 8.↵
   1. Blumfield E,
   2. Moore MM,
   3. Drake MK, et al

   . Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report. Pediatr Radiol 2017;47:665–73 doi:10.1007/s00247-017-3807-z pmid:28283728

   CrossRefPubMed
9. 9.↵
   1. Rossi Espagnet MC,
   2. Bernardi B,
   3. Pasquini L, et al

   . Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol 2017;47:1345–52 doi:10.1007/s00247-017-3874-1 pmid:28526896

   CrossRefPubMed
10. 10.↵
    1. Gulani V,
    2. Calamante F,
    3. Shellock FG, et al

    ; International Society for Magnetic Resonance in Medicine. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017;16:564–70 doi:10.1016/S1474-4422(17)30158-8 pmid:28653648

    CrossRefPubMed
11. 11.↵
    1. Kirchin MA,
    2. Pirovano G,
    3. Venetianer C, et al

    . Safety assessment of gadobenate dimeglumine (Multihance®): extended clinical experience from Phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001;14:281–94 doi:10.1002/jmri.1184 pmid:11536405

    CrossRefPubMed
12. 12.↵
    1. Shellock FG,
    2. Parker JR,
    3. Venetianer C, et al

    . Safety of gadobenate dimeglumine: summary of findings from clinical studies and post-marketing surveillance. Invest Radiol 2006;41:500–09 doi:10.1097/01.rli.0000209661.99225.c2 pmid:16763468

    CrossRefPubMed
13. 13.↵
    1. Bleicher AG,
    2. Kanal E.

    Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191:W307–11 doi:10.2214/AJR.07.3951 pmid:19020220

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Schneider G,
    2. Schürholz H,
    3. Kirchin MA, et al

    . Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children. Pediatr Radiol 2013;43:202–11 doi:10.1007/s00247-012-2498-8 pmid:23179483

    CrossRefPubMed
15. 15.↵
    1. Shen Y,
    2. Goerner FL,
    3. Snyder C, et al

    . T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol 2015;50:330–08 doi:10.1097/RLI.0000000000000132 pmid:25658049

    CrossRefPubMed
16. 16.↵
    1. Colosimo C,
    2. Demaerel P,
    3. Tortori-Donati P, et al

    . Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in pediatric subjects. Pediatr Radiol 2005;35:501–10 doi:10.1007/s00247-004-1392-4 pmid:15678342

    CrossRefPubMed
17. 17.↵
    1. Schneider G,
    2. Maas R,
    3. Schultze Kool L, et al

    . Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003;38:85–94 doi:10.1097/00004424-200302000-00003 pmid:12544071

    CrossRefPubMed
18. 18.↵
    1. Nandwana SB,
    2. Moreno CC,
    3. Osipow MT, et al

    . Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015;276:741–47 doi:10.1148/radiol.2015142423 pmid:25875973

    CrossRefPubMed
19. 19.↵
    1. Bruce R,
    2. Wentland AL,
    3. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol 2016;51:701–05 doi:10.1097/RLI.0000000000000259 pmid:26885631

    CrossRefPubMed
20. 20.↵
    1. Schneider GK,
    2. Stroeder J,
    3. Roditi G, et al

    . T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease. AJNR Am J Neuroradiol 2017;38:1799–806 doi:10.3174/ajnr.A5270 pmid:28642266

    Abstract/FREE Full Text
21. 21.↵
    1. Kinner S,
    2. Schubert TB,
    3. Bruce RJ, et al

    . Deep brain nuclei T1 shortening after gadobenate dimeglumine in children: influence of radiation and chemotherapy. AJNR Am J Neuroradiol 2018;39:24–30 doi:10.3174/ajnr.A5453 pmid:29146718

    Abstract/FREE Full Text
22. 22.↵
    MultiHance prescribing information in the USA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s016s017,021358s015s016lbl.pdf. Accessed September 5, 2019
23. 23.↵
    1. Elster AD,
    2. Moody DM,
    3. Ball MR

    et al. Is Gd-DTPA required for routine cranial MR imaging? Radiology 1989;173:231–38 doi:10.1148/radiology.173.1.2781014 pmid:2781014

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Schwartz GJ,
    2. Brion LP,
    3. Spitzer A.

    The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571–90 doi:10.1016/S0031-3955(16)36251-4 pmid:3588043

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Hellerstein S.

    Fluids and electrolytes: physiology. Pediatr Rev 1993;14:70–79 doi:10.1542/pir.14-2-70 pmid:8493184

    Abstract/FREE Full Text
26. 26.↵
    1. Bhargava R,
    2. Hahn G,
    3. Hirsch W, et al

    . Contrast-enhanced magnetic resonance imaging in pediatric patients: review and recommendations for current practice. Magn Reson Insights 2013;6:95–111 doi:10.4137/MRI.S12561] pmid:25114547

    CrossRefPubMed
27. 27.↵
    1. Raschle N,
    2. Zuk J,
    3. Ortiz-Mantilla S, et al

    . Pediatric neuroimaging in early childhood and infancy: challenges and practical guidelines. Ann N Y Acad Sci 2012;1252:43–50 doi:10.1111/j.1749-6632.2012.06457.x pmid:22524338

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Alcorn J,
    2. McNamara PJ.

    Ontogeny of hepatic and renal systemic clearance pathways in infants, Part I. Clin Pharmacokinet 2002;41:959–98 doi:10.2165/00003088-200241120-00003 pmid:12222995

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Fernandez E,
    2. Perez R,
    3. Hernandez A, et al

    . Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 2011;3:53–72 doi:10.3390/pharmaceutics3010053 pmid:24310425

    CrossRefPubMed
30. 30.↵
    1. Ginsberg G,
    2. Hattis D,
    3. Sonawane B, et al

    . Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66:185–200 doi:10.1093/toxsci/66.2.185 pmid:11896285

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Kunze C,
    2. Mentzel HJ,
    3. Krishnamurthy R, et al

    . Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Invest Radiol 2016;51:50–57 doi:10.1097/RLI.0000000000000204 pmid:26340504

    CrossRefPubMed
32. 32.↵
    1. Scala M,
    2. Koob M,
    3. de Buttet S, et al

    . A pharmacokinetics, efficacy, and safety study of gadoterate meglumine in pediatric subjects aged younger than 2 years. Invest Radiol 2018;53:70–79 doi:10.1097/RLI.0000000000000412 pmid:28906338

    CrossRefPubMed
33. 33.↵
    1. Emond S,
    2. Brunelle F.

    Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 2011;41:1401–06 doi:10.1007/s00247-011-2167-3 pmid:21786126

    CrossRefPubMed
34. 34.↵
    1. Bhargava R,
    2. Noga M.

    Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years: a single-center, observational study. Magn Reson Insights 2013;6:1–12 doi:10.4137/MRI.S10996 pmid:25114540

    CrossRefPubMed
35. 35.↵
    1. Hamm B,
    2. Thoeni RF,
    3. Gould RG, et al

    . Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417–23 doi:10.1148/radiology.190.2.8284392 pmid:8284392

    CrossRefPubMed
36. 36.↵
    1. Kanal E,
    2. Maravilla K,
    3. Rowley HA.

    Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014;35:2215–26 doi:10.3174/ajnr.A3917 pmid:24852287

    Abstract/FREE Full Text
37. 37.↵
    1. Vaneckova M,
    2. Herman M,
    3. Smith MP, et al

    . The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study). AJNR Am J Neuroradiol 2015;36:1589–98 doi:10.3174/ajnr.A4468 pmid:26185325

    Abstract/FREE Full Text
38. 38.↵
    1. Khouri Chalouhi K,
    2. Papini GD,
    3. Bandirali M, et al

    . Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI. Eur J Radiol 2014;83:1245–49 doi:10.1016/j.ejrad.2014.03.030 pmid:24816087

    CrossRefPubMed
39. 39.↵
    1. Huang B,
    2. Liang CH,
    3. Liu HJ, et al

    . Low dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0T using high-relaxivity contrast agents. Acta Radiol 2010;51:78–84 doi:10.3109/02841850903350178 pmid:19912078

    CrossRefPubMed
40. 40.↵
    1. Crisi G,
    2. Filice S,
    3. Erb G, et al

    . Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas. J Magn Reson Imaging 2017;45:500–06 doi:10.1002/jmri.25370 pmid:27373976

    CrossRefPubMed
41. 41.↵
    1. Filice S,
    2. Crisi G,
    3. Erb G.

    T2*-correction in dynamic contrast-enhanced magnetic resonance imaging of glioblastoma from a half dose of high-relaxivity contrast agent. J Comput Assist Tomogr 2017;41:816–21 doi:10.1097/RCT.0000000000000611 pmid:28708734

    CrossRefPubMed
42. 42.↵
    1. Murata N,
    2. Gonzalez-Cuyar LF,
    3. Murata K, et al

    . Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 2016;51:447–53 doi:10.1097/RLI.0000000000000252 pmid:26863577

    CrossRefPubMed
43. 43.↵
    1. Bussi S,
    2. Penard L,
    3. Bonafè R, et al

    . Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance^®) to neonatal and juvenile rats. Regul Toxicol Pharmacol 2018;92:268–27 doi:10.1016/j.yrtph.2017.12.016 pmid:29278694

    CrossRefPubMed